851776-29-9 Usage
Description
1,4,5,6-TETRAHYDRO-CYCLOPENTAPYRAZOLE-3-CARBONITRILE is a heterocyclic organic compound with the molecular formula C8H11N3. It features both a pyrazole and a cyano group, making it a unique structure of interest in pharmaceutical research and development.
Used in Pharmaceutical Research and Development:
1,4,5,6-TETRAHYDRO-CYCLOPENTAPYRAZOLE-3-CARBONITRILE is used as a key intermediate in the synthesis of new drugs and pharmaceutical compounds. Its unique structure and properties contribute to its potential in medicinal chemistry and drug discovery.
Used in Medicinal Chemistry:
1,4,5,6-TETRAHYDRO-CYCLOPENTAPYRAZOLE-3-CARBONITRILE is used as a building block for designing and developing novel pharmaceutical compounds, leveraging its heterocyclic nature to create molecules with specific therapeutic properties.
Used in Drug Discovery:
1,4,5,6-TETRAHYDRO-CYCLOPENTAPYRAZOLE-3-CARBONITRILE is utilized in the identification and optimization of new drug candidates, potentially leading to the discovery of innovative treatments for various diseases and conditions.
Used in Biological Research:
Due to its potential biological activities, 1,4,5,6-TETRAHYDRO-CYCLOPENTAPYRAZOLE-3-CARBONITRILE is of interest to researchers in the pharmaceutical industry, who may explore its interactions with biological systems and its effects on cellular processes.
Check Digit Verification of cas no
The CAS Registry Mumber 851776-29-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,1,7,7 and 6 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 851776-29:
(8*8)+(7*5)+(6*1)+(5*7)+(4*7)+(3*6)+(2*2)+(1*9)=199
199 % 10 = 9
So 851776-29-9 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3/c8-4-7-5-2-1-3-6(5)9-10-7/h1-3H2,(H,9,10)
851776-29-9Relevant articles and documents
Development of a scaleable synthesis of a partial nicotinic acid receptor agonist
Wilson, Robert D.,Cleator, Ed,Ashwood, Michael S.,Bio, Matthew M.,Brands, Karel M.J.,Davies, Antony J.,Dolling, Ulf-H,Emerson, Khateeta M.,Gibb, Andrew D.,Hands, David,McKeown, Arlene E.,Oliver, Steven F.,Reamer, Robert A.,Sheen, Faye J.,Stewart, Gavin W.,Zhou, George X.
experimental part, p. 543 - 547 (2010/04/22)
A practical and efficient synthesis of 1,4,5,6-tetrahydro-3-(1Htetrazol- 5-yl)cyclopenta[c]pyrazole, 1, is described. A new one-pot process has been developed, starting from the commercially available 1H-tetrazole-5-carboxylic acid-ethyl ester sodium salt which is reacted in a pseudo-Claisen condensation reaction with cyclopentanone, followed by the addition of hydrazine.
COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS
-
Page/Page column 75, (2010/11/30)
The invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist. In addition, the invention provides a
TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
-
Page/Page column 60, (2010/02/11)
The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present in
